Otsuka Pharmaceutical Co., Ltd.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$78.5M
Doctors Paid
204
Transactions
9,088
2024 Total
$727,395
Payment Breakdown by Category
Research$75.5M (96.1%)
Consulting$2.0M (2.5%)
Travel$533,044 (0.7%)
Royalty/License$115,484 (0.1%)
Food & Beverage$24,183 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $75.5M | 7,516 | 96.1% |
| Consulting Fee | $2.0M | 330 | 2.5% |
| Travel and Lodging | $533,044 | 743 | 0.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $412,491 | 87 | 0.5% |
| Royalty or License | $115,484 | 5 | 0.1% |
| Food and Beverage | $24,183 | 406 | 0.0% |
| Education | $16.74 | 1 | 0.0% |
Payments by Type
Research
$75.5M
7,516 transactions
General
$3.0M
1,572 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE DD-CKD INNO2VATE-CONVERSION | $25.3M | 4 | 1,518 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE NDD-CKD PRO2TECT-CORRECTION | $7.5M | 23 | 1,327 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML | $6.2M | 0 | 598 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE NDD-CKD PRO2TECT-CONVERSION | $4.6M | 5 | 1,209 |
| PHASE 1-2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF ASTX660 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS | $3.9M | 0 | 398 |
| A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF GUADECITABINE SGI-110 VERSUS TREATMENT CHOICE IN ADULTS WITH MYELODYSPLASTIC SYNDROMES MDS OR CHRONIC MYELOMONOCYTIC LEUKEMIA CMML PREVIOUSLY TREATED WITH HYPOMETHYLATING AGENTS | $3.6M | 0 | 222 |
| Phase 1 clinical study research for protocol VIS649-101, IND number 135282 | $2.2M | 0 | 1 |
| A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF SGI-110 VERSUS TREATMENT CHOICE TC IN ADULTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA AML WHO ARE NOT CONSIDERED CANDIDATES FOR INTENSIVE REMISSION INDUCTION CHEMOTHERAPY | $2.1M | 0 | 211 |
| A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF GUADECITABINE SGI-110 VERSUS TREATMENT CHOICE IN ADULTS WITH PREVIOUSLY TREATED ACUTE MYELOID LEUKEMIA AML | $1.7M | 0 | 185 |
| A PHASE 1-2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF ASTX029 IN SUBJECTS WITH ADVANCED SOLID TUMORS | $1.5M | 0 | 128 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE DD-CKD INNO2VATE - CORRECTIONCONVERSION | $1.4M | 14 | 380 |
| A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF GUADECITABINE (SGI-110) VERSUS TREATMENT CHOICE IN ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PREVIOUSLY TREATED WITH HYPOMETHYLATING AGENTS | $1.3M | 0 | 118 |
| A PHASE1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR CDAI E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS | $1.1M | 0 | 217 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) | $812,256 | 0 | 195 |
| A PHASE 1-2. DOSE ESCALATION. MULTICENTER STUDY OF TWO SUBCUTANEOUS REGIMENS OF SGI-110. A DNA HYPOMETHYLATING AGENT. IN SUBJECTS WITH INTERMEDIATE OR HIGH-RISK MYELODYSPLASTIC SYNDROMES MDS OR ACUTE MYELOGENOUS LEUKEMIA AML | $775,161 | 0 | 51 |
| A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE (ASTX727 LD) EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK (IPSS LOW OR INTERMEDIATE-1) MYELODYSPLASTIC SYNDROMES (MDS) | $747,500 | 0 | 119 |
| STUDY OF ASTX295 IN PATIENTS WITH SOLID TUMORS WITH WILD-TYPE P53 | $746,770 | 0 | 48 |
| A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE ASTX727 LD EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK IPSS LOW OR INTERMEDIATE-1 MYELODYSPLASTIC SYNDROMES MDS | $716,554 | 0 | 69 |
| Phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. | $716,490 | 0 | 1 |
| A PHASE II TRIAL TO ASSESS THE EFFICACY AND TOXICITY OF SGI-110 WITH DLI FOR THE TREATMENT OF AML OR MDS RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | $674,037 | 0 | 13 |
| A PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF HYPOMETHYLATING AGENT GUADECITABINE IN COMBINATION WITH CARBOPLATIN IN EXTENSIVE STAGE SMALL CELL LUNG CANCER | $496,241 | 0 | 34 |
| AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN PRIOR GUADECITABINE CLINICAL STUDIES | $491,661 | 0 | 67 |
| A PHASE 1B STUDY TO EVALUATE THE EFFECT OF FOOD ON PHARMACOKINETICS OF ASTX727 CEDAZURIDINE AND DECITABINE IN SUBJECTS WITH MYELODYSPLASIC SYNDROMES OR ACUTE MYELOID LEUKEMIA | $488,355 | 0 | 44 |
| Gene Therapy for Alport Syndrome The goal is to develop novel AAV vector mediated-gene therapy to treat Alport syndrome and to establish its proof-of-concept using mice and rhesus macaques. | $479,083 | 0 | 1 |
| A PHASE I STUDY OF SGI-110 COMBINED WITH IRINOTECAN FOLLOWED BY A RANDOMIZED PHASE II STUDY OF SGI-110 COMBINED WITH IRINOTECAN VERSUS REGORAFENIB IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS | $437,609 | 0 | 16 |
| A MULTI-PHASE, DOSE-ESCALATION FOLLOWED BY AN OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY OF ORAL ASTX030 (CEDAZURIDINE AND AZACITIDINE GIVEN IN COMBINATION) VERSUS SUBCUTANEOUS AZACITIDINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), OR ACUTE MYELOID LEUKEMIA (AML) | $394,043 | 0 | 21 |
| GENOTYPIC VARIATION IN RESPONSES TO ASTX727 AMONG PATIENTS WITH MDS | $336,335 | 0 | 1 |
| AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN PRIOR CLINICAL STUDIES OF ASTX727 (STANDARD DOSE) | $327,102 | 0 | 30 |
| A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF GUADECITABINE (SGI-110) VERSUS TREATMENT CHOICE IN ADULTS WITH PREVIOUSLY TREATED ACUTE MYELOID LEUKEMIA (AML) | $305,858 | 0 | 61 |
| A PHASE 1, PARALLEL, OPEN-LABEL STUDY OF THE SAFETY AND TOLERABILITY, PHARMACOKINETICS, AND ANTILEUKEMIC ACTIVITY OF ASTX660 AS A SINGLE AGENT AND IN COMBINATION WITH ASTX727 IN SUBJECTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) | $294,103 | 0 | 15 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Rheumatology | $935,259 | 7 | $133,608 |
| Medical Oncology | $521,138 | 18 | $28,952 |
| Internal Medicine | $448,956 | 37 | $12,134 |
| Psychiatry | $390,386 | 11 | $35,490 |
| Nephrology | $294,497 | 61 | $4,828 |
| Hematology & Oncology | $240,708 | 22 | $10,941 |
| Cardiovascular Disease | $101,330 | 7 | $14,476 |
| Geriatric Psychiatry | $98,794 | 2 | $49,397 |
| Endocrinology, Diabetes & Metabolism | $30,610 | 1 | $30,610 |
| Hematology | $24,467 | 3 | $8,156 |
| Gastroenterology | $22,803 | 4 | $5,701 |
| Transplant Surgery | $22,000 | 1 | $22,000 |
| Neurology | $15,449 | 2 | $7,724 |
| Pediatrics | $7,103 | 1 | $7,103 |
| Student in an Organized Health Care Education/Training Program | $5,423 | 2 | $2,712 |
| Pediatric Nephrology | $4,375 | 2 | $2,188 |
| Diagnostic Radiology | $3,600 | 1 | $3,600 |
| Pediatric Allergy/Immunology | $2,500 | 1 | $2,500 |
| Pediatric Hematology-Oncology | $2,363 | 1 | $2,363 |
| Allergy & Immunology | $2,025 | 1 | $2,025 |
| Hospitalist | $1,511 | 3 | $503.56 |
| General Practice | $1,271 | 1 | $1,271 |
| Infectious Disease | $1,200 | 1 | $1,200 |
| Pain Medicine | $1,125 | 1 | $1,125 |
| Emergency Medicine | $1,119 | 1 | $1,119 |
| Critical Care Medicine | $1,006 | 1 | $1,006 |
| Family Medicine | $897.35 | 1 | $897.35 |
| Specialist | $467.42 | 2 | $233.71 |
| Health Educator | $264.66 | 1 | $264.66 |
| Surgery | $150.29 | 1 | $150.29 |
| Dermatology | $108.11 | 1 | $108.11 |
| Neurological Surgery | $88.27 | 1 | $88.27 |
| Thoracic Surgery (Cardiothoracic Vascular Surgery) | $50.00 | 1 | $50.00 |
| Addiction Medicine | $26.64 | 1 | $26.64 |
Top Paid Doctors — Page 8
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Andrew Barbas, Md, MD | Surgery | Durham, NC | $150.29 | $0 |
| Bruce Julian | Nephrology | Birmingham, AL | $141.59 | $0 |
| Dr. Patrick Nachman, Md, MD | Nephrology | Minneapolis, MN | $141.59 | $0 |
| Andrew Levey, M.d, M.D | Nephrology | Boston, MA | $110.65 | $0 |
| Brian Poligone, Md, MD | Dermatology | Fairport, NY | $108.11 | $0 |
| Dr. Bob Carter, M.d., Ph.d, M.D., PH.D | Neurological Surgery | Boston, MA | $88.27 | $0 |
| Hagop Kantarjian, Md, MD | Medical Oncology | Houston, TX | $84.13 | $0 |
| Bart Scott | Medical Oncology | Seattle, WA | $81.08 | $0 |
| Dr. Casey O'connell, M.d, M.D | Hematology & Oncology | Los Angeles, CA | $69.48 | $0 |
| Jamile Shammo, M.d, M.D | Hematology | Chicago, IL | $69.48 | $0 |
| David Weinstock, Md, MD | Medical Oncology | Boston, MA | $65.18 | $0 |
| Dr. Amy Dezern, Md, MD | Medical Oncology | Baltimore, MD | $61.59 | $0 |
| Patricia Lorusso, Do, DO | Internal Medicine | Detroit, MI | $52.33 | $0 |
| Joseph Ladowski, Md, MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Indianapolis, IN | $50.00 | $0 |
| Tamara Moyo, Md, MD | Hematology | Charlotte, NC | $47.60 | $0 |
| Nashat Gabrail, M.d, M.D | Specialist | Canton, OH | $41.63 | $0 |
| David Claxton, Md, MD | Hematology & Oncology | Hershey, PA | $40.57 | $0 |
| Dr. Lindsay Wilde, Md, MD | Medical Oncology | Philadelphia, PA | $37.51 | $0 |
| Dr. Margaret Kasner, M.d, M.D | Hematology & Oncology | Philadelphia, PA | $37.51 | $0 |
| Gina Keiffer | Internal Medicine | Philadelphia, PA | $37.51 | $0 |
| Dr. Ubaldo Martinez Outschoorn, M.d, M.D | Internal Medicine | Philadelphia, PA | $37.51 | $0 |
| Dr. Prapti Patel, M.d, M.D | Hematology & Oncology | Dallas, TX | $36.27 | $0 |
| Robert Swift, M.d., Ph.d, M.D., PH.D | Addiction Medicine | Providence, RI | $26.64 | $0 |
| Olatoyosi Odenike | Hematology & Oncology | Chicago, IL | $25.32 | $0 |
| Laura Michaelis, Md, MD | Internal Medicine | Milwaukee, WI | $25.32 | $0 |
Ad
Top Products
- REXULTI $263,483
- ICLUSIG $212,290
Payment Categories
- Food & Beverage $24,183
- Consulting $2.0M
- Travel & Lodging $533,044
- Research $75.5M
- Royalties $115,484
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. has made $78.5M in payments to 204 healthcare providers, recorded across 9,088 transactions in the CMS Open Payments database. In 2024, the company paid $727,395. The top product by payment volume is REXULTI ($263,483).
Payments were distributed across 34 medical specialties. The top specialty by payment amount is Rheumatology ($935,259 to 7 doctors).
Payment categories include: Food & Beverage ($24,183), Consulting ($2.0M), Research ($75.5M), Travel & Lodging ($533,044), Royalties ($115,484).